TherapeuticsMD (TXMD) Liabilities from Discontinued Operations (2010 - 2026)
TherapeuticsMD's (TXMD) quarterly Liabilities from Discontinued Operations came in at 2667000.0 in Q1 2026, down 4.24% YoY from 2785000.0 in Q1 2025, and little changed on a QoQ basis from 2667000.0 in Q4 2025.
TherapeuticsMD (TXMD) Liabilities from Discontinued Operations (2010 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has 7 years of Liabilities from Discontinued Operations data on file, last reported at 2667000.0 in Q1 2026.
- Quarterly Liabilities from Discontinued Operations fell 4.24% year-over-year to 2667000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2667000.0 (down 4.24% YoY) and the FY2025 annual result came in at 2667000.0, down 4.1% from the prior year.
- Liabilities from Discontinued Operations steadied at 2667000.0 in Q1 2026, from 2667000.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 25831000.0 in Q4 2022 to a low of 1372000.0 in Q2 2023.
- A 5-year average of 4947214.29 and a median of 2783000.0 in 2024 frame the typical range for Liabilities from Discontinued Operations.
- Annual changes were most pronounced in 2023 — Liabilities from Discontinued Operations slumped 85.7% — and 2024, when it soared 337.61%.
- Tracing TXMD's Liabilities from Discontinued Operations over 5 years: stood at 25831000.0 in 2022, then tumbled by 85.7% to 3694000.0 in 2023, then declined by 24.72% to 2781000.0 in 2024, then decreased by 4.1% to 2667000.0 in 2025, then changed by 0.0% to 2667000.0 in 2026.
- The last three Liabilities from Discontinued Operations figures came in at 2667000.0 (Q1 2026), 2667000.0 (Q4 2025), and 2667000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | TherapeuticsMD | 23.78 Mn | 14.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.67 Mn |
| Jun 30, 2026 | 2.67 Mn |
| Mar 31, 2026 | 2.67 Mn |
| Mar 31, 2026 | 2.67 Mn |
| Dec 31, 2025 | 2.67 Mn |
| Dec 31, 2025 | 2.67 Mn |
| Sep 30, 2025 | 2.67 Mn |
| Sep 30, 2025 | 2.67 Mn |
| Jun 30, 2025 | 2.72 Mn |
| Jun 30, 2025 | 2.72 Mn |
| Mar 31, 2025 | 2.79 Mn |
| Mar 31, 2025 | 2.79 Mn |
| Dec 31, 2024 | 2.78 Mn |
| Dec 31, 2024 | 2.78 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Jun 30, 2024 | 6.00 Mn |
| Jun 30, 2024 | 6.00 Mn |
| Mar 31, 2024 | 3.61 Mn |
| Mar 31, 2024 | 3.61 Mn |